The Medical University of Vienna is a university located in Vienna, Austria. It is the direct successor of the faculty of medicine of the University of Vienna, founded in 1365 by Rudolf IV, Duke of Austria. Thus it is the oldest medical school in the German–speaking world, and it was the second medical faculty in the Holy Roman Empire, after the Charles University of Prague.The Medical University of Vienna is the largest medical organisation in Austria, as well as one of the top-level research institutions in Europe and provides Europe's largest hospital, the Vienna General Hospital, with all of its medical staff.It consists of 31 university clinics and clinical institutes, 12 medical-theoretical departments which perform around 48,000 operations each year. The Vienna General Hospital has about 100,000 patients treated as inpatients and 605,000 treated as outpatients each year.There have been seven Nobel prize laureates affiliated with the medical faculty, and fifteen in total with the University of Vienna. These include Robert Bárány, Julius Wagner-Jauregg and Karl Landsteiner, the discoverer of the ABO blood type system and the Rhesus factor. Sigmund Freud qualified as a doctor at the medical faculty and worked as a doctor and lecturer at the General Hospital, carrying out research into cerebral palsy, aphasia and microscopic neuroanatomy.In the 2014-15 Times Higher Education Rankings, Medical University of Vienna is listed among the top 15 medical schools in Europe and 49th in the world. .In 2014, there were 6,016 candidate applications for 660 places in medicine proper and 80 in dentistry, which corresponds to an admission rate of about 12 percent. Admission is based upon ranking in an admission test, called "MedAT", which is carried out every summer in conjunction with the two other public medical schools of Austria, Medical University of Graz and Innsbruck Medical University. Wikipedia.
Medical University of Vienna | Date: 2014-12-19
The invention relates to an aortic catheter (1) for insertion into the aorta (A), having a flexible tube (2), two occlusion balloons (3, 4), which are spaced part from one another and each of which is connected to a supply line (5, 6) for supplying a pumping medium (7) for inflating the occlusion balloons (3, 4), having at least one opening (8) arranged between the occlusion balloons (3, 4) in the tube (2) for supplying a cooling medium (9), which at least one opening (8) is connected to a first cooling medium supply line (10) running in the tube (2), and also relates to a resuscitation set (22) with such an aortic catheter (1), and a distal port (13) for supplying a cooling medium (9) in the direction of cerebral vessels is disposed in the tube (2), which distal port (13) is connected to a second cooling medium supply line (14) running in the tube (2).
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: ICT-29-2016 | Award Amount: 4.00M | Year: 2017
More than 450.000 people are diagnosed with esophageal cancer (EC) each-year worldwide and approximately 400.000 die from the disease. Esophageal cancer is the eighth most commonly diagnosed cancer, but it is the sixth leading cause of cancer-related death, with incidence rates steeply rising. Risk factors, including gastroesophageal reflux disease and Barretts esophagus, may diagnostically implicate more than 300 million people worldwide. Nevertheless, the disease is detected late due to limitations in current diagnostic procedures leading to adverse prognosis and high treatment costs. ESOTRAC will change the landscape of esophageal diagnosis, over existing methods, based on cross-sectional optoacoustic and optical coherence endoscopy. The dual-modality system delivers a set of early-cancer imaging features necessary for improving early diagnosis, saving lives and leading to 3-5 Billion annual savings for the healthcare system. OCT provides micron scale subsurface morphological information based on photon scattering and optoacoustics provides deeper penetration and complementary pathophysiological features based on photon absorption. ESOTRAC develops novel photonic components (light sources, optical/optoacoustic scopes) and innovates novel medical system designs. Then, it performs pilot studies to investigate the functionality of the new endoscope and deliver a novel imaging-feature portfolio offering improved and earlier diagnosis. A central ESOTRAC ambition is that the new endoscope will become the new EC diagnostic standard by enabling quantitative and label-free three-dimensional endoscopy of early cancer with tremendous potential to impact esophageal care. ESOTRAC leverages European investment and know-how and strengthens the prospects of economic growth by leading the market position in endoscopic imaging.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: FETPROACT-01-2016 | Award Amount: 4.94M | Year: 2017
This consortium will pioneer disruptive technology for bio-electronic medicine to provide much needed therapies for cardiorespiratory and functional neurological disease. The technology implements small neural networks known as central pattern generators (CPG) to deliver fit-and-forget bio-electronic implants that respond to physiological feedback in real time, are safer, simpler, non-invasive, and have autonomy exceeding the patient lifespan. Multichannel neurons will be made to compete on analogue chips to obtain flexible motor sequences underpinned by a wide parameter space. By building large scale nonlinear optimization tools and using them to assimilate electrophysiological data, we will develop a method for automatically finding the network parameters that accurately reproduce biological motor sequences and their adaptation to multiple physiological inputs. In this way, we will have resolved the issue of programming analogue CPGs which has long been the obstacle to using neural chips in medicine. An adaptive pacemaker will be constructed, tested, validated and trialled on animal models of atrio-ventricular block and left bundle branch block to demonstrate the benefits of heart rate adaptation, beat-to-beat cardiac resynchronization and respiratory sinus arrhythmia. By providing novel therapy for arrhythmias, heart failure and their comorbidities such as sleep apnoea and hypertension, CResPace will extend patients life and increase quality of life.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: FETOPEN-01-2016-2017 | Award Amount: 3.76M | Year: 2017
The physical laws of diffraction generally limit the spatial resolution of optical systems, being about 200 nm for light in the visible range. Within ChipScope we want to overcome this limit by developing the scientific and technological basis for a completely new approach to optical superresolution, based on semiconductor nano Light Emitting Diode (nanoLED) arrays with individual pixel operation. The core idea of ChipScope is to use spatially resolved illumination instead of spatially resolved detection for achieving microscopy functionality with superresolution. This will be made possible by developing chip-based nanoLED arrays with light emitting diode (LED) dimensions and distances much smaller than the wavelength of visible light (i.e. <50 nm). Thus, ChipScope will develop the highest resolution LED arrays in the world. These new devices will enable novel science in general and superresolution in particular. Making optical superresolution ubiquitously available is expected to lead to foundational breakthroughs in virtually every field of research and technology that makes use of optical microscopes. Within the project, the first chip-sized ChipScope microscopes will be developed, tested, calibrated and compared with state-of-the-art microscopy systems. During the course of the project, a game changing real-time imaging device for scientific investigation of living tissue will be used to study the in-cell mechanisms in Chronic Obstructive Pulmonary Disease (COPD) syndrome as a proof-of-concept of the new science and applications that will follow.
Agency: European Commission | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2016 | Award Amount: 2.54M | Year: 2017
The EN-ACTI2NG program (European Network on Anti-Cancer Immuno-Therapy Improvement by modification of CAR and TCR Interactions and Nanoscale Geometry) emanates from the recent clinical evidence that T cells expressing engineered tumor-specific immune receptors can eradicate certain tumors that do not respond to conventional treatment. To obtain T cells with reactivity to a wider array of tumors and to improve efficiency and on- and off-target toxicity are current challenges Therefore the EN-ACTI2NG program aims 1) to train PhD students with expertise in development of new and improved T cell-mediated cancer immuno-therapies; 2) to endow the PhD students with the ability to establish efficient communication between the academic and industrial research environments and between scientists and the general public; 3) to improve T cell mediated anti-cancer immuno-therapy by the identification and development of new cancer-specific immune receptors and enhancing their function by identifying and modifying their molecular mechanism of action. To reach these objectives we have designed individual research projects ranging from biophysical analysis of immune receptors, via molecular modification of their structure and testing their tumor killing capacity in cell-based and pre-clinical assays to product development. Secondments will assure that each PhD student will be exposed to these complementary approaches and that there will be synergic feedback between the projects, producing innovative results that could otherwise not be achieved. Extensive training in research-specific skills, career development and a continuous training in communication skills will allow the PhD students to become facilitators of the process of transformation of scientific innovation into products with social and economic value. As such, the EN-ACTI2NG program should contribute to overcoming the more general challenge of converting the European Community into an innovation-driven society.
ReGenHeart - Clinical development and proof of principle testing of new regenerative VEGF-D therapy for cost-effective treatment of refractory anginaA phase II randomized, double-blinded, placebo-controlled study
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: SC1-PM-11-2016-2017 | Award Amount: 5.93M | Year: 2017
Chronic angina pectoris is a debilitating chronic disease, a subgroup of these patients suffers from refractory angina which unfortunately cant be controlled by medical therapy (angioplasty or surgery). Refractory angina is a substantial burden on the individual and healthcare system, in Europe there are 100,000 new cases per year, annual mortality of these patients is relatively low (<4%) thus refractory angina patients suffer multiple hospitalizations and low levels of health-related quality of life. The ReGenHeart project is based on extensive preclinical work and a phase I safety, feasibility and dose-finding clinical study recently completed by the consortium. The project will conduct a multicentre, randomized, placebo-controlled, double-blinded Phase II clinical study to provide proof of concept and clinical validation for a new, percutaneous, cost-efficient therapy for refractory angina patients. Using our optimized catheter-mediated intramyocardial approach with AdenoVEGF-D, which has never been used in man before our phase I trial, we aim to induce regenerative changes supported by therapeutic angiogenesis in the affected area of a patients heart and, in a single procedure, reduce the burden on the individual and their health service. The proposed trial is ready to proceed, subject to final regulatory approval in the six European clinical centres. 180 CCS class 2-3 refractory angina patients will be recruited, which will allow us to assess the benefits of therapy to patients who still have potential to respond to the regenerative therapy. Patients will be randomized 2:1 to either the gene therapy or placebo arms. Trial follow up, at 6 and 12 months, will assess how far they can walk in 6 minutes (primary endpoint) and also by their CCS angina score, quality of life, so-called MACE endpoints and several advanced PET and MRI imaging endpoints.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: SC1-PM-09-2016 | Award Amount: 4.95M | Year: 2017
TYPE 1 DIABETES is one of the most COMMON CHRONIC diseases in children with a RAPID increase in number of cases particularly in young children. Type 1 diabetes is associated with LIFE-LONG dependency on insulin administration. POOR glucose control leads to diabetes COMPLICATIONS, e.g. eye, heart, kidney disease, including BRAIN changes in young children. Episodes of VERY LOW glucose levels may be life threatening and are a major complication. The ARTIFICIAL PANCREAS addresses the problem of LOW and HIGH glucose levels by delivering insulin BELOW and ABOVE pre-set amounts according to real-time sensor GLUCOSE levels, combining glucose SENSOR, insulin PUMP, and CONTROL ALGORITHM. The Artificial pancreas promises to TRANSFORM management of type 1 diabetes but EVIDENCE supporting its use during FREE LIVING in YOUNG CHILDREN is MISSING. The project evaluates the biomedical, psychosocial, and cost effectiveness of NOVEL INDIVIDUALISED artificial pancreas in young children aged 1 to 7 years with type 1 diabetes. Following a PILOT (n=24), in the MAIN study (n=94) half of the participants (n=47) will be treated over 12 MONTHS by the ARTIFICIAL PANCREAS and the other half (n=47) by STATE-OF-THE-ART PREDICTIVE LOW GLUCOSE MANAGEMENT insulin pump therapy. Each treatment will last ONE YEAR. QUALITY OF LIFE will be assessed and semi-structured INTERVIEWS conducted to understand the impact on daily life. HEALTH TECHNOLOGY ASSESSMENT will support reimbursement. The project will OPTIMISE artificial pancreas and SPEARHEAD SYSTEM-WIDE improvements in health care quality and health outcomes in YOUNG CHILDERN with TYPE 1 DIABETES who live with the disease LONGEST. By IMPROVING THERAPEUTIC OUTCOMES, the project will CHANGE clinical practice and INFLUENCE national and international treatment guidelines making the artificial pancreas WIDELY ACCEPTABLE as the state-of-art treatment modality in young children.
Holzer M.,Medical University of Vienna
New England Journal of Medicine | Year: 2010
A 62-year-old man collapses on the street, and emergency medical personnel who are called to the scene find that he is not breathing and that he has no pulse. The first recorded cardiac rhythm is ventricular fibrillation. Advanced cardiac life-support measures, including intubation, a total dose of 2 mg of epinephrine, and six defibrillation attempts, restore spontaneous circulation 22 minutes after the onset of the event. On admission to the emergency department, his condition is hemodynamically stable and he has adequate oxygenation and ventilation, but he is still comatose. A neurologic examination reveals reactive pupils and a positive cough reflex. The core body temperature is 35.5°C. A diagnosis of the post-cardiac arrest syndrome with coma is made. An intensive care specialist evaluates the patient and recommends the immediate initiation of targeted temperature management. Copyright © 2010 Massachusetts Medical Society.
Seitz C.,Medical University of Vienna
European urology | Year: 2012
Incidence, prevention, and management of complications of percutaneous nephrolitholapaxy (PNL) still lack consensus. To review the epidemiology of complications and their prevention and management. A literature review was performed using the PubMed database between 2001 and May 1, 2011, restricted to human species, adults, and the English language. The Medline search used a strategy including medical subject headings (MeSH) and free-text protocols with the keywords percutaneous, nephrolithotomy, PCNL, PNL, urolithiasis, complications, and Clavien, and the MeSH terms nephrostomy, percutaneous/adverse effects, and intraoperative complications or postoperative complications. Assessing the epidemiology of complications is difficult because definitions of complications and their management still lack consensus. For a reproducible quality assessment, data should be obtained in a standardized manner, allowing for comparison. An approach is the validated Dindo-modified Clavien system, which was originally reported by seven studies. No deviation from the normal postoperative course (Clavien 0) was observed in 76.7% of PNL procedures. Including deviations from the normal postoperative course without the need for pharmacologic treatment or interventions (Clavien 1) would add up to 88.1%. Clavien 2 complications including blood transfusion and parenteral nutrition occurred in 7%; Clavien 3 complications requiring intervention in 4.1.%; Clavien 4, life-threatening complications, in 0.6%; and Clavien 5, mortality, in 0.04%. High-quality data on complication management of rare but potentially debilitating complications are scarce and consist mainly of case reports. Complications after PNL can be kept to a minimum in experienced hands with the development of new techniques and improved technology. A modified procedure-specific Clavien classification should be established that would need to be validated in prospective trials. Copyright © 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Lion T.,Medical University of Vienna
Clinical Microbiology Reviews | Year: 2014
Human adenoviruses (HAdVs) are an important cause of infections in both immunocompetent and immunocompromised individuals, and they continue to provide clinical challenges pertaining to diagnostics and treatment. The growing number of HAdV types identified by genomic analysis, as well as the improved understanding of the sites of viral persistence and reactivation, requires continuous adaptions of diagnostic approaches to facilitate timely detection and monitoring of HAdV infections. In view of the clinical relevance of life-threatening HAdV diseases in the immunocompromised setting, there is an urgent need for highly effective treatment modalities lacking major side effects. The present review summarizes the recent progress in the understanding and management of HAdV infections. © 2014, American Society for Microbiology. All Rights Reserved.